LEADER 03523nam 22005655 450 001 9910157502003321 005 20221101212949.0 010 $a3-319-26512-1 024 7 $a10.1007/978-3-319-26512-4 035 $a(CKB)3710000001001381 035 $a(MiAaPQ)EBC4774778 035 $a(DE-He213)978-3-319-26512-4 035 $a(PPN)198341334 035 $a(EXLCZ)993710000001001381 100 $a20170102d2016 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aClinical Research Involving Pregnant Women /$fedited by Françoise Baylis, Angela Ballantyne 205 $a1st ed. 2016. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016. 215 $a1 online resource (306 pages) 225 1 $aResearch Ethics Forum,$x2212-9529 ;$v3 320 $aIncludes bibliographical references at the end of each chapters and index. 330 $aThis book discusses ?how? to respectfully and responsibly include pregnant women in clinical research. In sharp contrast, the existing literature predominantly focuses on the reasons ?why? the inclusion of pregnant women in clinical research is necessary ? viz., to develop effective treatments for women during pregnancy, to promote fetal safety, to reduce harm to women and fetuses from suboptimal care, and to allow access to the benefits of research participation. This book supports the shift to a new default position, whereby pregnant women are included in clinical research unless researchers argue convincingly for their exclusion. This shift raises many as yet unexplored ethical and policy questions about existing barriers to the equitable inclusion of pregnant women in research. This book is original in three key ways. First, it presents an unparalleled depth of analysis of the ethics of research with pregnant women, bringing together many of the key authors in this field as well as experts in research ethics and in vulnerability who have not previously applied their work to pregnant women. Second, it includes innovative theoretical work in ethics and disease specific case studies that highlight the current complexity and future challenges of research involving pregnant women. Third, the book brings together authors who argue both for and against including more pregnant women in formal clinical trials. . 410 0$aResearch Ethics Forum,$x2212-9529 ;$v3 606 $aMedical ethics 606 $aMaternal and child health services 606 $aEthics 606 $aTheory of Medicine/Bioethics$3https://scigraph.springernature.com/ontologies/product-market-codes/H66000 606 $aMaternal and Child Health$3https://scigraph.springernature.com/ontologies/product-market-codes/H27025 606 $aEthics$3https://scigraph.springernature.com/ontologies/product-market-codes/E14000 615 0$aMedical ethics. 615 0$aMaternal and child health services. 615 0$aEthics. 615 14$aTheory of Medicine/Bioethics. 615 24$aMaternal and Child Health. 615 24$aEthics. 676 $a616.0072 702 $aBaylis$b Françoise$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aBallantyne$b Angela$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910157502003321 996 $aClinical Research Involving Pregnant Women$92513362 997 $aUNINA LEADER 04916nam 22005175 450 001 9910254851903321 005 20200703120209.0 010 $a9781484230602 010 $a1484230604 024 7 $a10.1007/978-1-4842-3060-2 035 $a(CKB)4100000001040854 035 $a(DE-He213)978-1-4842-3060-2 035 $a(MiAaPQ)EBC5144563 035 $a(CaSebORM)9781484230602 035 $a(PPN)221255575 035 $a(OCoLC)1077473909 035 $a(OCoLC)on1077473909 035 $a(EXLCZ)994100000001040854 100 $a20171111d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBuilding a HIPAA-Compliant Cybersecurity Program $eUsing NIST 800-30 and CSF to Secure Protected Health Information /$fby Eric C. Thompson 205 $a1st ed. 2017. 210 1$aBerkeley, CA :$cApress :$cImprint: Apress,$d2017. 215 $a1 online resource (XXII, 297 p. 67 illus., 29 illus. in color.) 300 $aIncludes index. 311 08$a9781484230596 311 08$a1484230590 320 $aIncludes bibliographical references. 327 $aPart I: Why Risk Assessment and Analysis -- Chapter 1: Not If, But When -- Chapter 2: Meeting Regulator Expectations -- Chapter 3: Selecting Security Measures -- Part II: Assessing and Analyzing Risk -- Chapter 4: Inventory Your ePHI -- Chapter 5: Who Wants Health Information -- Chapter 6: Weaknesses Waiting to Be Exploited -- Chapter 7: Is It Really This Bad? -- Chapter 8: Increasing Program Maturity -- Chapter 9: Targeted Non-technical Testing -- Chapter 10: Targeted Technical Testing -- Part III: Applying the Results to Everyday Needs -- Chapter 11: Refreshing the Risk Register -- Chapter 12: The Cybersecurity Roadmap -- Part IV: Continuous Improvement -- Chapter 13: Investing for Risk Reduction -- Chapter 14: Third Party-Risk: Beyond the BAA -- Chapter 15: Social Media, BYOD, IOT and Portability -- Chapter 16: Risk Treatment and Management -- Chapter 17: Customizing the Risk Analysis -- Chapter 18: Think Offensively -- Appendix A. NIST CSF Internal Controls -- Appendix B. NIST CSF to HIPAA Crosswalk -- Appendix C: Risk Analysis Templates.- . 330 $aUse this book to learn how to conduct a timely and thorough Risk Analysis and Assessment documenting all risks to the confidentiality, integrity, and availability of electronic Protected Health Information (ePHI), which is a key component of the HIPAA Security Rule. The requirement is a focus area for the Department of Health and Human Services (HHS) Office for Civil Rights (OCR) during breach investigations and compliance audits. This book lays out a plan for healthcare organizations of all types to successfully comply with these requirements and use the output to build upon the cybersecurity program.   With the proliferation of cybersecurity breaches, the number of healthcare providers, payers, and business associates investigated by the OCR has risen significantly. It is not unusual for additional penalties to be levied when victims of breaches cannot demonstrate that an enterprise-wide risk assessment exists, comprehensive enough to document all of the risks to ePHI. Why is it that so many covered entities and business associates fail to comply with this fundamental safeguard? Building a HIPAA Compliant Cybersecurity Program cuts through the confusion and ambiguity of regulatory requirements and provides detailed guidance to help readers: Understand and document all known instances where patient data exist Know what regulators want and expect from the risk analysis process Assess and analyze the level of severity that each risk poses to ePHI Focus on the beneficial outcomes of the process: understanding real risks, and optimizing deployment of resources and alignment with business objectives What You?ll Learn: Use NIST 800-30 to execute a risk analysis and assessment, which meets the expectations of regulators such as the Office for Civil Rights (OCR) Understand why this is not just a compliance exercise, but a way to take back control of protecting ePHI Leverage the risk analysis process to improve your cybersecurity program Know the value of integrating technical assessments to further define risk management activities Employ an iterative process that continuously assesses the environment to identify improvement opportunities. 606 $aData protection 606 $aSecurity$3https://scigraph.springernature.com/ontologies/product-market-codes/I28000 615 0$aData protection. 615 14$aSecurity. 676 $a610.289 700 $aThompson$b Eric C$4aut$4http://id.loc.gov/vocabulary/relators/aut$0917128 801 0$bUMI 801 1$bUMI 906 $aBOOK 912 $a9910254851903321 996 $aBuilding a HIPAA-Compliant Cybersecurity Program$92056106 997 $aUNINA